Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine
- PMID: 10617681
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine
Abstract
Dexfenfluramine was approved in the United States for long-term use as an appetite suppressant until it was reported to be associated with valvular heart disease. The valvular changes (myofibroblast proliferation) are histopathologically indistinguishable from those observed in carcinoid disease or after long-term exposure to 5-hydroxytryptamine (5-HT)(2)-preferring ergot drugs (ergotamine, methysergide). 5-HT(2) receptor stimulation is known to cause fibroblast mitogenesis, which could contribute to this lesion. To elucidate the mechanism of "fen-phen"-associated valvular lesions, we examined the interaction of fenfluramine and its metabolite norfenfluramine with 5-HT(2) receptor subtypes and examined the expression of these receptors in human and porcine heart valves. Fenfluramine binds weakly to 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptors. In contrast, norfenfluramine exhibited high affinity for 5-HT(2B) and 5-HT(2C) receptors and more moderate affinity for 5-HT(2A) receptors. In cells expressing recombinant 5-HT(2B) receptors, norfenfluramine potently stimulated the hydrolysis of inositol phosphates, increased intracellular Ca(2+), and activated the mitogen-activated protein kinase cascade, the latter of which has been linked to mitogenic actions of the 5-HT(2B) receptor. The level of 5-HT(2B) and 5-HT(2A) receptor transcripts in heart valves was at least 300-fold higher than the levels of 5-HT(2C) receptor transcript, which were barely detectable. We propose that preferential stimulation of valvular 5-HT(2B) receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT(2A) receptor activation) may contribute to valvular fibroplasia in humans.
Similar articles
-
Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.Mol Pharmacol. 2005 Jul;68(1):20-33. doi: 10.1124/mol.104.009266. Epub 2005 Apr 14. Mol Pharmacol. 2005. PMID: 15831837
-
3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.Mol Pharmacol. 2003 Jun;63(6):1223-9. doi: 10.1124/mol.63.6.1223. Mol Pharmacol. 2003. PMID: 12761331
-
The fenfluramine metabolite (+)-norfenfluramine is vasoactive.J Pharmacol Exp Ther. 2004 May;309(2):845-52. doi: 10.1124/jpet.103.060806. Epub 2004 Jan 29. J Pharmacol Exp Ther. 2004. PMID: 14752059
-
Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.Mol Interv. 2005 Oct;5(5):282-91. doi: 10.1124/mi.5.5.8. Mol Interv. 2005. PMID: 16249524 Review.
-
Serotonergic drugs and valvular heart disease.Expert Opin Drug Saf. 2009 May;8(3):317-29. doi: 10.1517/14740330902931524. Expert Opin Drug Saf. 2009. PMID: 19505264 Free PMC article. Review.
Cited by
-
Stereoselective Analysis of the Antiseizure Activity of Fenfluramine and Norfenfluramine in Mice: Is l-Norfenfluramine a Better Follow-Up Compound to Racemic-Fenfluramine?Int J Mol Sci. 2024 Feb 21;25(5):2522. doi: 10.3390/ijms25052522. Int J Mol Sci. 2024. PMID: 38473769 Free PMC article.
-
Effects of hallucinogenic drugs on the human heart.Front Pharmacol. 2024 Feb 2;15:1334218. doi: 10.3389/fphar.2024.1334218. eCollection 2024. Front Pharmacol. 2024. PMID: 38370480 Free PMC article. Review.
-
Effects of cabergoline and dimethylcabergoline on the sexual behavior of male rats.Psychopharmacology (Berl). 2024 Apr;241(4):717-726. doi: 10.1007/s00213-023-06501-9. Epub 2023 Nov 16. Psychopharmacology (Berl). 2024. PMID: 37968530
-
μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges.Front Pharmacol. 2023 Oct 11;14:1239159. doi: 10.3389/fphar.2023.1239159. eCollection 2023. Front Pharmacol. 2023. PMID: 37886127 Free PMC article. Review.
-
Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding.Neuropsychiatr Dis Treat. 2023 Sep 26;19:2013-2025. doi: 10.2147/NDT.S417676. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37790801 Free PMC article. Review.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Miscellaneous